WallStSmart

Merck & Company Inc (MRK)vsSeaboard Corporation (SEB)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 562% more annual revenue ($65.01B vs $9.82B). MRK leads profitability with a 28.1% profit margin vs 4.0%. SEB appears more attractively valued with a PEG of 0.65. SEB earns a higher WallStSmart Score of 65/100 (B-).

MRK

Buy

59

out of 100

Grade: C

Growth: 4.0Profit: 9.5Value: 4.7Quality: 4.8
Piotroski: 3/9

SEB

Strong Buy

65

out of 100

Grade: B-

Growth: 6.0Profit: 4.5Value: 10.0Quality: 8.5
Piotroski: 5/9Altman Z: 3.59
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-141.2%)

Margin of Safety

-141.2%

Fair Value

$49.50

Current Price

$119.37

$69.87 premium

UndervaluedFair: $49.50Overvalued
SEBUndervalued (+71.0%)

Margin of Safety

+71.0%

Fair Value

$19183.79

Current Price

$5405.30

$13778.49 discount

UndervaluedFair: $19183.79Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK6 strengths · Avg: 9.2/10
Market CapQuality
$287.71B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
36.9%10/10

Every $100 of equity generates 37 in profit

Operating MarginProfitability
32.8%10/10

Strong operational efficiency at 32.8%

Profit MarginProfitability
28.1%9/10

Keeps 28 of every $100 in revenue as profit

P/E RatioValuation
16.0x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$1.82B8/10

Generating 1.8B in free cash flow

SEB5 strengths · Avg: 9.6/10
P/E RatioValuation
9.8x10/10

Attractively priced relative to earnings

Price/BookValuation
1.0x10/10

Reasonable price relative to book value

EPS GrowthGrowth
67.5%10/10

Earnings expanding 67.5% YoY

Altman Z-ScoreHealth
3.5910/10

Safe zone — low bankruptcy risk

PEG RatioValuation
0.658/10

Growing faster than its price suggests

Areas to Watch

MRK3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.492/10

Expensive relative to growth rate

EPS GrowthGrowth
-19.3%2/10

Earnings declined 19.3%

SEB2 concerns · Avg: 3.0/10
Profit MarginProfitability
4.0%3/10

4.0% margin — thin

Operating MarginProfitability
3.3%3/10

Operating margin of 3.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.

Bull Case : SEB

The strongest argument for SEB centers on P/E Ratio, Price/Book, EPS Growth. Revenue growth of 14.5% demonstrates continued momentum. PEG of 0.65 suggests the stock is reasonably priced for its growth.

Bear Case : MRK

The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.

Bear Case : SEB

The primary concerns for SEB are Profit Margin, Operating Margin. Thin 4.0% margins leave little buffer for downturns.

Key Dynamics to Monitor

SEB carries more volatility with a beta of 0.37 — expect wider price swings.

SEB is growing revenue faster at 14.5% — sustainability is the question.

MRK generates stronger free cash flow (1.8B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SEB scores higher overall (65/100 vs 59/100) and 14.5% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Seaboard Corporation

INDUSTRIALS · CONGLOMERATES · USA

Seaboard Corporation is a global agribusiness and transportation company. The company is headquartered in Merriam, Kansas.

Visit Website →

Want to dig deeper into these stocks?